Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... HOUSTON , March 31, 2015 ... at the American Association of Orthodontics 2015 Annual ... leading orthodontists present scientific lectures on AcceleDent ® ... the leader in accelerated orthodontics, AcceleDent is a ... orthodontic treatment by as much as 50 percent ...
(Date:3/31/2015)... ALTO, Calif. , March 31, 2015  Frequentz ... visibility, has released a white paper to help the ... the 2013 Drug Supply Chain Security Act (DSCSA). The ... various stages of the GS1 EPCIS Standard(s) ... detailed outlook on the product tracing requirements that need ...
(Date:3/31/2015)... 31, 2015  Mark Farrah Associates (MFA), ... (MA) plans in their recent analysis brief.  According ... enrolled in Medicare Advantage plans as of March ... members year-over-year.  54.3 million people are eligible for ... Medicaid Services (CMS), with an unpenetrated market of ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates 2
(Date:3/31/2015)... The New Jersey Chapter of the ... two administrators from Windsor Healthcare Communities, a leading ... Jersey, to two key leadership roles at this ... administrator for Abingdon Care & Rehabilitation Center of ... administrator of Canterbury Care & Rehabilitation Center at ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Tickets are ... show and Denver tradition since 1973. The 2015 Spring ... of Showtime on Ice. On April 24 in partnership ... event and opening night tribute to the Pat Bowlen ... A portion of the opening event proceeds will go ...
(Date:3/31/2015)... March 31, 2015 Indiana Fiber ... Service Provider, announces that Joink, LLC selected IFN ... According to Cory Childs, IFN Enterprise Sales ... specifically targeted at Internet Service Providers, Telecom companies, ... service provides Joink with diverse protected transport from ...
(Date:3/31/2015)... March 31, 2015 Rising rates of ... forced researchers and surgeons to better analyze and investigate ... used for repair. A recent study published ... systematic review of 1,016 young, very active patients to ... , “This is the first review to examine ...
(Date:3/31/2015)... Azilen Technologies adds yet another feather ... Company’ award at GESIA 2015. The firm earned this ... Award GESIA 2015. This marks Azilen’s second triumph at ... previously won the ‘Best Product Innovation’ award at GESIA ... development, enterprise mobility solutions and open source technologies. With ...
Breaking Medicine News(10 mins):Health News:Abingdon Care & Rehabilitation Center’s Administrator Elected President of N.J. Chapter of the American College of Health Care Administrators 2Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 2Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 3Health News:ACL Failure Risks Increased in Young Patients Using Allografts 2Health News:Azilen Technologies Receives ‘Best Product Development Company’ Award at GESIA 2015 2
... youngsters lose weight by concentrating on the way they look, ... them// gorge even more, according to a recent study. ... to change their eating habits than those who are happy ... that getting children of all shapes and sizes to think ...
... has revealed that the risk of atherosclerosis in diabetics ... is characterized by// thickening and hardening of artery walls. ... atherosclerosis. ,This study, conducted by researchers at ... a decrease in the risk of developing atherosclerosis in ...
... Incidences of breast cancer are twice as much within a ... month due to this disease. Scientists have issued a warning// ... may be the reason for this escalation of breast cancer. ... which have very similar structures as compared to the female ...
... of suspected chikungunya fever in Kerala will not affect the ... Tuesday. ,"As the World Health Organisation (WHO) has ... here is not chikungunya, things have cheered up. There have ... booked to travel to Kerala," Balakrishnan told reporters here. ...
... claimed yet another life, taking the death toll in the ... into city hospitals// with the mosquito-borne viral disease showing no ... is now 1,631, with 83 new patients admitted in the ... of the virus is 55-year-old Pritam of Faridabad town close ...
... yoga, pranayama and meditation besides controlled breathing techniques to ... Art of Living Foundation//. ,Encouraged by the efficacy ... chikungunya, a mosquito-borne disease that can prove fatal, the ... India to cater to people suffering from the disease. ...
Cached Medicine News:Health News:Obese Kids Unmotivated byWeight Loss campaigns 2Health News:One More Victim Succumbs to Dengue in Delhi 2Health News:Yoga and Meditation May be Helpful to Combat Chikungunya 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: